Check for updates

OPEN ACCESS

EDITED BY Sebhat Erqou, Brown University, United States

REVIEWED BY

Long Zhou, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, China Chunyu Li, Sichuan University, China

*CORRESPONDENCE

Demeng Xia demengxia@163.com Xiaobin Sun xbsun1197@163.com

[†]These authors have contributed equally to this work

SPECIALTY SECTION

This article was submitted to Cardiovascular Epidemiology and Prevention, a section of the journal Frontiers in Cardiovascular Medicine

RECEIVED 23 April 2022 ACCEPTED 16 August 2022 PUBLISHED 02 September 2022

CITATION

Wu K, Li A, Liu L, Shu T, Xia D and Sun X (2022) Inflammatory bowel disease and cardiovascular disease: A two-sample Mendelian randomization analysis. *Front. Cardiovasc. Med.* 9:927120. doi: 10.3389/fcvm.2022.927120

COPYRIGHT

© 2022 Wu, Li, Liu, Shu, Xia and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or

reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Inflammatory bowel disease and cardiovascular disease: A two-sample Mendelian randomization analysis

Kaiwen Wu^{1†}, Aoshuang Li^{1†}, Lei Liu^{2†}, Tao Shu¹, Demeng Xia^{3*} and Xiaobin Sun^{1*}

¹Department of Gastroenterology, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, China, ²Medical Research Center, The Third People's Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, China, ³Luodian Clinical Drug Research Center, Shanghai Baoshan Luodian Hospital, Shanghai University, Shanghai, China

Background: Although epidemiological studies have shown a positive relationship between inflammatory bowel disease (IBD) and risk of cardiovascular disease (CVD) outcomes, a solid causal relationship has not been established. Thus, a two-sample Mendelian randomization (MR) study was conducted to explore the potential causal effect between IBD and CVD outcomes.

Methods: We performed a two-sample MR analysis to analyze the causal effect of the IBD on CVD outcome by using summary-level genome-wide association studies of European descent. The inverse-variance weighted (IVW) method was used as the main MR analysis, main MR analysis, with complementary analyses of MR Egger, maximum likelihood, weighted median, penalized weighted media, simple mode, weighted mode, and MR-PRESSO methods. Multiple sensitivity analyses were used to evaluate the robustness of our results.

Results: All *P*-values were greater than 0.05 in the IVW method, showing no evidence of a causal association between circulating IBD and CVD. Similar results were observed by using other MR methods. No evidence of heterogeneity, pleiotropy, or outlier single-nucleotide polymorphisms was detected. Sensitivity analyses demonstrated the robustness of the results.

Conclusion: The findings of this study provided no evidence to support that IBD has a large effect on risk of CVD outcomes, which is in contrast to many previous observational reports. Further studies are needed to determine the potential mechanism of association identified in observational studies.

KEYWORDS

cardiovascular diseases, inflammatory bowel disease, Mendelian randomization, genome-wide association study, causation

Introduction

Cardiovascular disease (CVD) is a general term for all cardiovascular and brain diseases related to vasculopathy, mainly heart failure, coronary heart disease, arrhythmia, stroke and cerebral infarction (1, 2). Globally, CVDs are the leading cause of death, morbidity and disability worldwide, causing the increase of social and economic burden. Owing to the severe clinical and social consequences of CVD, there is an urgent need for concerted efforts to identify risk factors leading to CVD for early prevention and intervention (3). The occurrence and progression of CVD may be driven by genetic or environmental factors. Besides, some epidemiological studies have shown a strong association between inflammatory disease and CVD outcomes (4).

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is an immune-mediated chronic inflammatory disease of the gastrointestinal tract, characterized by abdominal pain and diarrhea (5). IBD is often accompanied by systemic inflammation and other extraintestinal manifestations. More than 6.8 million patients are suffering from IBD worldwide (6).

Several studies have proved that IBD patients have higher rates of CVD outcomes. The high levels of C-reactive protein, circulating inflammatory cytokines, immunoglobulins G and M, antineutrophil cytoplasmic antibody, vascular endothelial growth factor, and interleukin-1 in patients with IBD can lead to elevated level of oxidative stress, endothelial dysfunction, prothrombotic state, microvascular, and macrovascular dysfunction, which could further promote the formation of atherosclerosis, hence, resulting in an increased risk of CVD outcomes (7-9). A cohort study of 28,833 IBD patients from Denmark with a 13-year follow-up showed that IBD is associated with the development of coronary atherosclerotic heart disease (10). Findings from previous systematic reviews and meta-analyses also indicated that patients with IBD may possess a higher risk of CVD outcomes (10-12). However, Sridhar et al. found no increased risk of myocardial ischemia, cardiomyopathy, conduction disorders, and embolic strokes in patients with IBD after adjusting for confounding factors such as hypertension, diabetes, and hyperlipidemia (13). Studies evaluating the association between IBD and risk of CVD outcomes have reported inconsistent results, most likely due to sample size limitations. Furthermore, observational epidemiological studies are susceptible to confounding and reverse causation (14). The causal relationship between IBD and CVD outcomes requires further investigations.

Although randomized controlled studies (RCTs) can prevent selection bias and blinded analysis is able to improve the reliability of the results, RCTs are difficult or impractical to perform for the sake of high economic cost, intensive labor, a great deal of resource and time, as well as ethical limitations (15).

Mendelian randomization (MR) is a method of studying genetic epidemiology that utilizes one or multiple genetic variants, such as single nucleotide polymorphisms (SNPs), to assess causal effects between exposures and outcomes (16). Compared with traditional observational epidemiological studies, MR follows the principle of allele separation and free recombination of non-alleles and is not affected by confounding factors (17). Because germline genetic variants are fixed at conception, MR studies are unaffected by the disease process and can avoid confounding and reverse causality, further mitigating the influence of confounding factors (18). Besides, the high measurement precision of genetic variation can prevent regression dilution bias caused by measurement error (19). In this study, a two-sample MR study was performed to explore the genetic association between IBD and CVD outcomes using large-scale publicly available genome-wide association study (GWAS) data.

Materials and methods

Data resources

Inflammatory bowel disease GWAS summary statistics were obtained from the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC),1 which included a total sample size of 65,642 participants of predominantly European ancestry (cases/controls for ulcerative colitis: 13,768/33,977 and Crohn's disease: 17,897/33,977) (20). The large-scale GWAS summary datasets of about 14 CVD outcomes phenotypes were obtained from United Kingdom Biobank, the FinnGen consortium, and large genetic consortia (21-24). Shah et al. (21) conducted a GWAS comprising 47,309 cases and 930,014 controls of European ancestry across 26 studies from the Heart Failure Molecular Epidemiology for Therapeutic Targets Consortium. Malik et al. (24) performed a genome-wide association meta-analysis in 440,328 European individuals (34,217 ischemic stroke patients and 406,111 controls), and discovered 22 new stroke risk loci. These datasets were used for MR analysis. The full data set can be downloaded from https://gwas.mrcieu.ac.uk/ and https://www.finngen.fi/en. The detailed information is provided in Figure 1. MR studies were conducted by using summary statistics from GWAS, which were ethically approved and publicly available on the

Abbreviations: IBD, inflammatory bowel disease; CVD, cardiovascular disease; MR, Mendelian randomization; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; HERMES, Heart Failure Molecular Epidemiology for Therapeutic Targets Consortium; MRC-IEU, Medical Research Council-Integrative Epidemiology Unit.

¹ https://www.ibdgenetics.org/

Outcome		Data source	Case/Control	ropulation	IVW (randon								
					Exposure O	PR 95	5%CI						P Value
Coronary heart	t disease	CARDIoGRAMplusC4D	42,096/ 89,818	European	CD 0.	.9991 0.	.9803-1.0183			Ι	Ι		0.9291
				European	UC 1.	.0009 0.	.9757-1.0267				—		0.9472
Coronary ather	rosclerosis	Neale lab	14,334/346,860	European	CD 1.	.0001 0.	.9992-1.0009						0.8769
				European	UC 0.	.9993 0.	.9983-1.0003						0.1520
Heart failure		Consortium (Shah S et al.)	47,309/930,014	European	CD 0.	.9975 0.	.9753-1.0136						0.5570
				European			.9753-1.0136						0.5570
Cardiomyopathy	the c	The FinnGen consortium	4,606/218,984	European			.9192-1.0128				-		0.9186
Venous thromboembolism		The Philippen consortium	4,000/218,984							•	-		
				European			.9324-1.0651			•		-	0.1487
		Neale lab	4,620/356,574	European			.9994-1.0004				•		0.8188
				European			.9988-1.0001				•		0.0892
Deep venous thrombosis		MRC-IEU	9,241/453,692	European			.9993-1.0006				•		0.8258
Atrial fibrillation				European	UC 0.	.9999 0.	.9993-1.0006				•		0.8258
		Consortium (Jonas B. Nielsen et.al)	60,620/970,216	European	CD 0.	.9917 0.	.9778-1.0057				-		0.2448
				European	UC 1.	.0003 0.	.9821-1.0189			H	-		0.9729
Pulmonary embolism		Neale lab	2,118/359,076	European	CD 1.	.0000 0.	.9997-1.0004						0.8269
				European	UC 0.	9998 0.	.9993-1.0002						0.2820
Peripheral arterial disease		Neale lab	1,456/461,554	European	CD 0.	.9998 0.	.9996-1.0001						0.1842
r empirerar arter	ernar ansease	Treate hab	1,450,401,554	European			.9997-1.0002						0.6409
		0 2 ALB - 5									•		
Ischemic stroke	æ	Consortium (Malik et.al)	34,217/406,111				.9810-1.0216						0.9184
				European			.9828-1.0299			-	+ I		0.6131
Intracerebral ha	naemmorrhage	The FinnGen consortium	1,687/201,146				.9346-1.0668					-	0.9649
				European	UC 1.	.0058 0.	.9328-1.0845				•		0.8808
Subarachnoid h	hemorrhage	The FinnGen consortium	1,961/281,638	European	CD 0.	.9581 0.	.8891-1.0325			+			0.2620
				European	UC 1.	.0184 0.	.9177-1.1302		-		+		0.7313
Cerebral infarc	ction	MRC-IEU	1,420/461,590	European	CD 0.	.9999 0.	.9996-1.0001						0.2846
				European	UC L		9997-1.0003						0.9636
Athenosclerosis	ie	The FinnGen consortium	11,189/288,638	European	CD 1.	.0032 0.	.9769-1.0302						0.8132
Atherosclerosis		The Finite Constitution	11,107,200,050	European			.9697-1.0344				_		0.9252
								0.8000 0.85	00 0.9000				1.1500
Outcome		Data source	Case/Control	Population	IVW (fix-effe	ect)							
Outcome		Data source	Case/Control	Population	IVW (fix-effe								
	rt diseaso				Exposure O)R 9:	5%CI						P Value
Outcome Coronary heart	rt disease	Data source CARDioGRAMplusC4D	Case/Control 42,096/ 89,818	European	Exposure O CD 0.	9 R 9 :	5%CI .9815-1.0171						P Value 0.9242
Coronary heart		CARDIoGRAMplusC4D	42,096/ 89,818	European European	Exposure O CD 0. UC 1.	98 99 99991 0. 0009 0.	5%CI .9815-1.0171 .9764-1.0260			,			P Value 0.9242 0.9457
				European European European	Exposure O CD 0. UC 1. CD 1.	R 9 .9991 0. .0009 0. .0001 0.	5%CI .9815-1.0171 .9764-1.0260 .9993-1.0008			,			P Value 0.9242 0.9457 0.8701
Coronary heart Coronary ather		CARDioGRAMplusC4D Neale lab	42,096/ 89,818 14,334/346,860	European European European European	Exposure O CD 0. UC 1. CD 1. UC 0.	PR 99 9991 0. 0009 0. 0001 0. 9993 0.	5%CI .9815-1.0171 .9764-1.0260 .9993-1.0008 .9983-1.0002						P Value 0.9242 0.9457 0.8701 0.1356
Coronary heart		CARDIoGRAMplusC4D	42,096/ 89,818	European European European European	Exposure O CD 0. UC 1. CD 0. UC 1. UC 0. UC 0.	PR 9 .9991 0. .0009 0. .0001 0. .9993 0. .9993 0. .99975 0.	5%CI 19815-1.0171 19764-1.0260 19993-1.0008 19983-1.0002 19824-1.0129				• •		P Value 0.9242 0.9457 0.8701 0.1356 0.7502
Coronary heart Coronary ather Heart failure	rosclerosis	CARDIoGRAMplusC4D Neate lab Consortium (Shah S et al.)	42,096/ 89,818 14,334/346,860 47,309/930,014	European European European European European	Exposure O CD 0. UC 1. CD 0. UC 0. UC 0. UC 0. UC 0. UC 0. UC 0.	R 9! .9991 0. .0009 0. .0001 0. .9993 0. .9975 0. .9942 0.	5%CI .9815-1.0171 .9764-1.0260 .9993-1.0008 .9993-1.0002 .9824-1.0129 .9772-1.0116			,	• • •		P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131
Coronary heart Coronary ather	rosclerosis	CARDioGRAMplusC4D Neale lab	42,096/ 89,818 14,334/346,860 47,309/930,014	European European European European European European	Exposure O CD 0. UC 1. CD 0. UC 0. UC 0. UC 0. CD 0. CD 0. CD 0. UC 0. UC 0. CD 0.	R 9! .9991 0. .0009 0. .0001 0. .9993 0. .9975 0. .9942 0. .9649 0.	5%CI 19815-1.0171 19764-1.0260 19993-1.0008 19993-1.0008 19993-1.0002 19824-1.0129 1972-1.0116 19192-1.0128			P 	↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓		P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487
Coronary heart Coronary ather Heart failure Cardiomyopath	erosclerosis	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinnGen consortium	42,096/ 89,818 14,334/346,860 47,309/930,014 4,606/218,984	European European European European European European European	Exposure O CD 0. UC 1. CD 0. UC 0.	R 9! .9991 0. .0009 0. .0001 0. .9993 0. .9995 0. .9942 0. .9649 0. .9965 0.	5%CI .9815-1.0171 .9764-1.0260 .9993-1.0008 .9983-1.0002 .9824-1.0129 .9772-1.0116 .9192-1.0128 .9324-1.0651			, , ,			P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186
Coronary heart Coronary ather Heart failure	erosclerosis	CARDIoGRAMplusC4D Neate lab Consortium (Shah S et al.)	42,096/ 89,818 14,334/346,860 47,309/930,014	European European European European European European European	Exposure O CD 0. UC 1. CD 0. UC 0.	R 9! .9991 0. .0009 0. .0001 0. .9993 0. .9995 0. .9942 0. .9649 0. .9965 0.	5%CI 19815-1.0171 19764-1.0260 19993-1.0008 19993-1.0008 19993-1.0002 19824-1.0129 1972-1.0116 19192-1.0128			, , ,			P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487
Coronary heart Coronary ather Heart failure Cardiomyopath	erosclerosis	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinnGen consortium	42,096/ 89,818 14,334/346,860 47,309/930,014 4,606/218,984	European European European European European European European	Exposure O CD 0 UC 1 CD 0 UC 0 CD 0	R 92 .9991 0. .0009 0. .0011 0. .9993 0. .9993 0. .9994 0. .9995 0. .9965 0. .9995 0. .9995 0.	5%CI .9815-1.0171 .9764-1.0260 .9993-1.0008 .9983-1.0002 .9824-1.0129 .9772-1.0116 .9192-1.0128 .9324-1.0651			, , ,			P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromb	thy boembolism	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinnGen consortium	42,096/ 89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/ 356,574	European European European European European European European European	Exposure O CD 0. UC 1. CD 0. CD 0. UC 0.	R 9:2 .9991 0. .0009 0. .0011 0. .9993 0. .9993 0. .9994 0. .9995 0. .99965 0. .9995 0.	5%C1 9815-1.0171 19764-1.0260 9993-1.0008 9993-1.0008 99824-1.0129 99727-1.0116 9192-1.0128 99324-1.0651 99324-1.0651 9995-1.0000			, , ,			P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658
Coronary heart Coronary ather Heart failure Cardiomyopath	thy boembolism	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinnGen consortium Neale lab	42,096/ 89,818 14,334/346,860 47,309/930,014 4,606/218,984	European European European European European European European European European European	Exposure O CD 0. UC 1. CD 0. CD 0. UC 0. CD 0. UC 0. CD 0. UC 0.	PR 92 .9991 0. .0009 0. .0001 0. .9993 0. .9993 0. .9994 0. .99649 0. .9965 0. .9995 0. .9995 0. .9995 0.	5%CI 99815-1.0171 9764-1.0260 9993-1.0008 9983-1.0002 99824-1002 99824-1003 99924-10128 99924-1004 99985-1.0004 99983-1.0003			, , ,			P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1431 0.9186 0.8030 0.0658 0.5384
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromt Deep venous th	crosclerosis thy nboembolism thrombosis	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinanGen consortium Neale lab MRC-IEU	42,096/ 89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/ 356,574 9,241/453,692	European European European European European European European European European European	Exposure O CD 0. UC 1. CD 0. UC 0. CD 0. UC 0.	R 92 .9991 0. .0009 0. .0011 0. .9993 0. .9993 0. .9994 0. .9995 0. .9965 0. .9995 0. .9995 0. .9998 0. .99999 0.	5%C1 9815-1.0171 9993-1.0008 9993-1.0008 9983-1.0002 98824-1.0129 99772-1.0116 9192-1.0128 9192-1.0128 9324-1.0051 9993-1.0000 9993-1.0000			, , ,			P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658 0.5384 0.5384 0.8258
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromb	crosclerosis thy nboembolism thrombosis	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinnGen consortium Neale lab	42,096/ 89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/ 356,574	European European European European European European European European European European European	Exposure O CD 0 UC 1. CD 0. UC 0. CD 0. UC 0. CD 0. UC 0. CD 0. UC 0. CD 0. UC 0. UC 0. UC 0.	R 92 .9991 0. .0009 0. .0011 0. .9993 0. .9993 0. .9995 0. .9942 0. .9955 0. .9995 0. .9995 0. .9995 0. .9998 0. .9999 0. .99917 0.	5%C1 99831-1.0171 19764-1.0260 9993-1.0008 19983-1.0002 19972-1.0116 9192-1.0128 19972-1.0116 91995-1.0004 9995-1.0004			, , ,			P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658 0.5384 0.8258 0.1973
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromh Deep venous th Atrial fibrillatio	thy aboembolism thrombosis	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinaGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et.al)	42,096/ 89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/356,574 9,241/453,692 60,620/970,216	European European European European European European European European European European European European	Exposure O CD 0. UC 1. CD 0. UC 1.	PR 92 .9991 0. .0009 0. .0001 0. .9993 0. .9993 0. .9994 0. .9945 0. .9995 0. .9998 0. .9999 0. .9999 0. .9999 0. .99917 0. .0003 0.	5%C1 9/815-1.0171 9/764-1.0260 9/993-1.0002 9/824-1.0129 9/824-1.0129 9/824-1.0129 9/824-1.0129 9/9272-1.0146 9/995-1.0000 9/995-1.0000 9/995-1.0000 9/995-1.0000 9/995-1.0006 9/995-1.0006 9/992-1.0046			, , ,			P Valu 0.9242 0.9457 0.8701 0.356 0.7502 0.5131 0.487 0.9186 0.8303 0.658 0.658 0.658 0.6384 0.8388 0.6384 0.6384 0.6384 0.6384 0.6384 0.6384 0.6384 0.6384 0.6384 0.6384 0.6385 0.6395 0.6385000000000000000000000000000000000000
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromt Deep venous th	thy aboembolism thrombosis	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinanGen consortium Neale lab MRC-IEU	42,096/ 89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/ 356,574 9,241/453,692	European European European European European European European European European European European European European	Exposure O CD 0. CD 1. UC 0. CD 0. CD 0. CD 0. UC 0. CD 0. UC 0. CD 0. UC 0. CD 0. UC 0. CD 0. CD 0. CD 0. CD 0. UC 0. CD 0. UC 0. CD 0. CD 0. UC 0. CD 0. UC 1. CD 1.	PR 92 .9991 0. .0009 0. .0011 0. .9993 0. .9994 0. .9995 0. .9995 0. .9995 0. .9998 0. .9999 0. .9999 0. .99917 0. .00003 0. .00000 0.	5%CI 5/815-1.0171 5/993-1.0260 5/993-1.0008 5/9983-1.0002 5/9824-1.0129 5/972-1.0116 6/9192-1.0128 5/995-1.0004 5/995-1.0000 5/995-1.0006 5/995-1.0006 5/953-1.0016 5/953-1			, , ,			P Valu 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658 0.5384 0.5384 0.4255 0.9059 0.9059 0.9059 0.9051 0.9059 0.9051 0.9052 0.9051 0.9052 0.9051 0.9052 0.9051 0.9052 0.9052 0.9051 0.9052
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromh Deep venous th Atrial fibrillati- Pulmonary eml	rosclerosis thy thoembolism thrombosis ion	CARDIoGRAMpIusC4D Neale lab Consortium (Shah S et al.) The FinaGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et.al) Neale lab	42,096/89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/356,574 9,241/453,692 60,620/970,216 2,118/359,076	European European European European European European European European European European European European European European European	Exposure O CD 0. CC 1. UC 0. CD 0. UC 1. UC 1. UC 1. UC 1. UC 0.	PR 99 .9991 0. .0009 0. .0001 0. .9993 0. .9993 0. .9993 0. .9993 0. .9995 0. .9995 0. .9998 0. .9999 0. .9991 0. .9995 0. .9999 0. .99917 0. .0003 0. .00004 0. .9998 0.	5%C1 9815-1.0171 9764-1.0260 9993-1.0002 9824-1.0129 9993-1.0002 9993-1.0003 9995-1.0004 9995-1.0004 9995-1.0004 9993-1.0003 9993-1.0003			, , ,			P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658 0.6384 0.8258 0.1973 0.9695 0.8113 0.2469
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromt Deep venous th Atrial fibrillatio	rosclerosis thy thoembolism thrombosis ion	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinaGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et.al)	42,096/ 89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/356,574 9,241/453,692 60,620/970,216	European European European European European European European European European European European European European European European European European	Exposure O CD 0 CD 1 CD 1 CD 0 CD 1 CD 1 CD 0 CD 1 CD 0 CD 0 CD 0 CD 0 CD 0 CD 0	PR 99 .9991 0. .0009 0. .0001 0. .9993 0. .9993 0. .9993 0. .9993 0. .9995 0. .9995 0. .9998 0. .9999 0. .9991 0. .9995 0. .9998 0. .0003 0. .0004 0. .9998 0. .9998 0. .9998 0.	5%C1 :9815-1.0171 :976-1.0260 :9993-1.0008 :9993-1.0008 :9824-1.0129 :9772-1.0116 :9192-1.0128 :9324-1.0051 :9985-1.0000 :9993-1.0003 :9993-1.0003 :9993-1.0003 :9993-1.0003 :9994-1.0002 :9994-1.0002			, ,			P Value 0.9242 0.937 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658 0.5384 0.8258 0.9733 0.9695 0.8113 0.2469 0.1475
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromh Deep venous th Atrial fibrillati- Pulmonary eml	rosclerosis thy thoembolism thrombosis ion	CARDIoGRAMpIusC4D Neale lab Consortium (Shah S et al.) The FinaGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et.al) Neale lab	42,096/89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/356,574 9,241/453,692 60,620/970,216 2,118/359,076	European European European European European European European European European European European European European European European	Exposure O CD 0 CD 1 CD 1 CD 0 CD 1 CD 1 CD 0 CD 1 CD 0 CD 0 CD 0 CD 0 CD 0 CD 0	PR 99 .9991 0. .0009 0. .0001 0. .9993 0. .9993 0. .9993 0. .9993 0. .9995 0. .9995 0. .9998 0. .9999 0. .9991 0. .9995 0. .9998 0. .0003 0. .0004 0. .9998 0. .9998 0. .9998 0.	5%C1 9815-1.0171 9764-1.0260 9993-1.0002 9824-1.0129 9993-1.0002 9993-1.0003 9995-1.0004 9995-1.0004 9995-1.0004 9993-1.0003 9993-1.0003			, , ,			P Value 0.9242 0.9457 0.87010 0.1356 0.5131 0.1487 0.9186 0.8030 0.0658 0.80458 0.8258 0.1973 0.9695 0.8113 0.2459
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromh Deep venous th Atrial fibrillati- Pulmonary eml	rroselerosis Ihy Iboembolism Ihrombosis ion Ioolism erial disease	CARDIoGRAMpIusC4D Neale lab Consortium (Shah S et al.) The FinaGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et.al) Neale lab	42,096/89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/356,574 9,241/453,692 60,620/970,216 2,118/359,076	European European European European European European European European European European European European European European European European European	Exposure CI CD 0 CD 1 CD 1 CD 0 UC 0 CD 0 UC 0 UC 0 UC 0 UC 1 CD 1 UC 0	PR 99 .9991 0. .0009 0. .0011 0. .9993 0. .9994 0. .9995 0. .9942 0. .9964 0. .9965 0. .9998 0. .9998 0. .99977 0. .00003 0. .00003 0. .9998 0. .9998 0. .9998 0. .9999 0.	5%C1 :9815-1.0171 :976-1.0260 :9993-1.0008 :9993-1.0008 :9824-1.0129 :9772-1.0116 :9192-1.0128 :9324-1.0051 :9985-1.0000 :9993-1.0003 :9993-1.0003 :9993-1.0003 :9993-1.0003 :9994-1.0002 :9994-1.0002			, , ,			P Value 0.9242 0.937 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658 0.5384 0.8258 0.9733 0.9695 0.8113 0.2469 0.1475
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromh Deep venous th Atrial fibrillati- Pulmonary eml Peripheral arter	rroselerosis Ihy Iboembolism Ihrombosis ion Ioolism erial disease	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinafGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et.al) Neale lab	42,096/89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/356,574 9,241/453,692 60,620/970,216 2,118/359,076 1,456/461,554	European European European European European European European European European European European European European European European European European	Exposure O CD 0. CD 1. UC 1. UC 0. CD 0. UC 0.	PR 99 0.0009 0. 0.0009 0. 0.0000 0. 0.0000 0. 0.0000 0. 0.0000 0. 0.0000 0. 0.0000 0. 0.0000 0. 0.0000 0. 0.99942 0. 0.99950 0. 9.9996 0. 9.9917 0. 0.0000 0. 9.99980 0. 9.99980 0. 9.99980 0. 9.99980 0. 9.99980 0. 9.99980 0. 9.99980 0. 9.99980 0. 9.99980 0. 9.99980 0. 9.99980 0. 9.99980 0. 9.99980 0. 9.99980 0. 9.99980 0.	5%CI 9815-1.0171 99764-1.0260 99951-1.0008 99951-1.0008 99951-1.0008 99951-1.0004 99951-1.0004 99951-1.0004 99951-1.0004 99951-1.0004 99971-1.0002 999971-1.0002			, , ,			P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658 0.5384 0.8258 0.1973 0.9655 0.8113 0.2469 0.1475 0.6409
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromh Deep venous th Atrial fibrillati Pulmonary end Peripheral artes Ischemic stroka	rrosclerosis hty hboembolism htrombosis ion hbolism erial disease se	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinafGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et.al) Neale lab	42,096/89,818 14,334/346,860 47,309/930,014 4,6606/218,984 4,620/356,574 9,241/453,692 60,620,970,216 60,620,970,216 1,456/461,554 34,217/406,111	European European European European European European European European European European European European European European European European European European European	Exposure O CD 0. CD 1. UC 1. UC 0. CD 0. UC 0. CD 0. CD 0. CD 0. CD 0. UC 0. CD 0. UC 0. CD 0. UC 0. CD 0. UC 1. UC 1.	PR 99 0.9991 0. 0.0009 0. 0.00001 0. 0.9913 0. 0.9913 0. 0.9913 0. 0.9913 0. 0.9913 0. 9.9942 0. 9.9945 0. 9.9998 0. 9.9999 0. 0.0001 0. 0.0003 0. 0.0004 0. 0.0005 0. 0.0006 0. 0.0006 0. 0.0001 0. 0.0001 0. 0.0001 0. 0.0001 0. 0.0001 0.	5%C1 						P Value 0.9242 0.9457 0.8701 0.1356 0.702 0.5131 0.1487 0.9186 0.8030 0.0658 0.8258 0.8258 0.8258 0.8113 0.2669 0.1475 0.6499 0.9094 0.9094 0.5703
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromh Deep venous th Atrial fibrillati- Pulmonary eml Peripheral arter	rrosclerosis hty hboembolism htrombosis ion hbolism erial disease se	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinaGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et al) Neale lab Neale lab Consortium (Malik et al)	42,096/89,818 14,334/346,860 47,309/930,014 4,6606/218,984 4,620/356,574 9,241/453,692 60,620,970,216 60,620,970,216 1,456/461,554 34,217/406,111	European European	Exposure O CD 0. CD 1. UC 1. UC 0. CD 0. UC 0. UC 0. CD 0. UC 0. CD 0. UC 0. CD 0. UC 0. CD 0. UC 1. UC 1. UC 1. CD 0.	PR 99 0.0000 0. 0.0000 0. 0.0001 0. 0.9933 0. 0.9939 0. 0.9942 0. 0.9945 0. 0.9946 0. 9.9947 0. 9.9948 0. 9.9949 0. 9.99949 0. 9.99947 0. 0.0000 0. 0.00000 0. 0.99948 0. 0.00000 0. 0.00000 0. 0.99949 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0.	5%CI 9815-1.0171 99764-1.0260 99951-1.0008 99951-1.0008 99951-1.0008 99951-1.0004 99921-1.0128 9324-1.0129 93954-1.0004 99954-1.0004 99954-1.0004 93994-1.0002 99974-1.0002 99974-1.0002 93974-1.0002 93974-1.0002 93974-1.0002 93974-1.0002			, , , ,			P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658 0.8304 0.6384 0.8258 0.1973 0.6459 0.8113 0.2469 0.1475 0.6409 0.9084 0.5784 0.5784
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromat Deep venous th Atrial fibrillati Pulmonary end Peripheral artee Ischemic stroka	rrosclerosis hy boembolism thrombosis ion abolism erial disease ce uaenmorthage	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinnGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et.al) Neale lab Neale lab Consortium (Malk et.al) The FinnGen consortium	42,096/89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/356,574 9,241/453,692 2,118/359,076 1,456/461,554 34,217/406,111 1,687/201,146	European European	Exposure O CD 0. UC 1. UC 0. UC 0. UC 0. UC 0. UC 0. CD 0. UC 0. CD 0. UC 0. UC 0. CD 0. UC 0. CD 0. UC 0. CD 0. UC 1. CD 1. CD 1. CD 1. CD 1. CD 1. CD 0. UC 1.	PR 99 0.0000 0. 0.0000 0. 0.0000 0. 0.993 0. 0.9993 0. 0.9942 0. 0.9954 0. 0.9964 0. 0.9964 0. 0.9995 0. 0.9996 0. 0.9998 0. 0.0000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00000 0. 0.00001 0. 0.00001 0. 0.00001 0. 0.00001 0. 0.00005 0.	5%C1 9815-1.0171 976-1.0260 9993-1.0002 9824-1.0129 9993-1.0002 9824-1.0129 9772-1.0116 9192-1.0128 9394-1.0001 9995-1.0004 9995-1.0004 9995-1.0003 9997-1.0003 9997-1.0003 9997-1.0003 9997-1.0003 9997-1.0002 9997-1.0002 9997-1.0002 9997-1.0002 9997-1.0002 9997-1.0002 9997-1.0002			, , , , , , , , , , , , , , , , , , ,			P Value 0.9242 0.9457 0.8701 0.1356 0.5131 0.1487 0.9186 0.8030 0.0658 0.6384 0.8258 0.1973 0.9695 0.8113 0.2469 0.1475 0.6409 0.9444 0.5793 0.9695
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromh Deep venous th Atrial fibrillati Pulmonary end Peripheral artes Ischemic stroka	rrosclerosis hy boembolism thrombosis ion abolism erial disease ce uaenmorthage	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinaGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et al) Neale lab Neale lab Consortium (Malik et al)	42,096/89,818 14,334/346,860 47,309/930,014 4,6606/218,984 4,620/356,574 9,241/453,692 60,620,970,216 60,620,970,216 1,456/461,554 34,217/406,111	European European	Exposure O CD 0 CD 1 CD 1 CD 0 CD 0 UC 0 CD 0 UC 0 UC 0 CD 0 UC 1	PR 99 0.9991 0. 0.0001 0. 0.0010 0. 0.001 0. 0.9993 0. 9.9943 0. 9.9945 0. 9.9945 0. 9.9945 0. 9.9945 0. 9.9945 0. 9.9946 0. 9.9949 0. 9.9949 0. 9.9949 0. 9.9949 0. 9.9949 0. 9.9949 0. 9.9949 0. 9.9949 0. 9.9949 0. 9.9949 0. 9.9949 0. 9.9949 0. 9.9949 0. 9.9949 0. 9.9940 0. 9.9941 0. 9.9942 0. 9.9945 0. 9.9581 0.	5%C1 9815-1071 99764-10260 9995-1.0002 9995-1.0002 9995-1.0002 9972-1.0016 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0003 9995-1.0003 9995-1.0003 9995-1.0002 9996-1.0001 9997-1.0002 9985-1.0193 9996-1.0001 9997-1.0002 9985-1.0193 9996-1.0001 9997-1.0002 9985-1.0013						P Value 0.9242 0.9457 0.8701 0.1356 0.7562 0.5131 0.1487 0.9186 0.8030 0.0658 0.588 0.5384 0.8258 0.6393 0.9695 0.8113 0.2669 0.1475 0.6409 0.9084 0.5733 0.9613 0.8808 0.80100 0.8010000000000
Coronary heart Coronary ather Heart failure Cardiomyopat Venous throm Deep venous th Atrial fibrillatis Pulmonary em Peripheral artee Ischemic stroko Intracerebral h Sabarachnoid I	rrosclerosis hty beembelism thrombosis ion erial disease es usemmorthage	CARDIOGRAMplusC4D Neale lab Consortium (Shah S et al.) The FianGen consortium Neale lab NRC-IEU Consortium (Jonas B. Nielsen et.al) Neale lab Consortium (Malik et.al) The FianGen consortium	42,096/ 89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/ 356,574 9,241/453,692 60,620,970,216 60,620,970,216 1,456/461,554 34,217/406,111 1,687/201,146 1,961/281,638	European European	Exposure O CD 0 CD 0 CD 1 CD 0 CD 1	R 99 0.0009 0. 0.0010 0. 0.001 0. 0.001 0. 0.001 0. 0.9993 0. 0.9993 0. 0.9996 0. 0.9998 0. 0.99998 0. 0.0000 0. 0.99998 0. 0.0000 0. 0.99998 0. 0.0000 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0. 9.99998 0.	5%C1 9815-1071 9764-10260 9995-1.0008 9983-1.0002 99824-10129 99824-10129 9972-1.0116 9192-1.0128 9324-1021 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0001 9995-1.0002 9995-1.0004 9995-1.0002 9995-1						P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658 0.5384 0.8258 0.1973 0.9695 0.8113 0.2469 0.1475 0.6409 0.9084 0.5793 0.9613 0.9613 0.8088 0.2258 0.6396
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromat Deep venous th Atrial fibrillati Pulmonary end Peripheral artee Ischemic stroka	rrosclerosis hty beembelism thrombosis ion erial disease es usemmorthage	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinnGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et.al) Neale lab Neale lab Consortium (Malk et.al) The FinnGen consortium	42,096/ 89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/ 356,574 9,241/453,692 60,620,970,216 60,620,970,216 1,456/461,554 34,217/406,111 1,687/201,146 1,961/281,638	European European	Exposure O CD 0. CD 1. UC 1. UC 0. UC 0. UC 0. UC 0. CD 0. UC 0. UC 0. UC 0. UC 0. CD 1. UC 0. CD 1. UC 0. UC 1. UC	R 9:9 R 9:9991 0. 0.0009 0. 0. 9:991 0. 0. 9:997 0. 0. 9:997 0. 0. 9:997 0. 0. 9:997 0. 0. 9:998 0. 0. 9:9998 0. 0. 9:9999 0. 0. 9:9998 0. 0. 0:0000 0. 0. 0:0001 0. 0. 0:0001 0. 0. 0:00101 0. 0. 0:0011 0. 0. 0:0011 0. 0. 0:0011 0. 0. 0:0011 0. 0. 0:0012 0. 0. 0:0013 0. 0. 0:0014 0. 0. 0:0015 0. 0. 0:0154 0. 0.	5%C1 9815-1.0171 976-1.0260 9993-1.0002 9993-1.0002 9993-1.0002 9993-1.0002 9993-1.0002 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0001 9997-1.0002 9977-0.001						P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658 0.5384 0.8258 0.1973 0.9695 0.8113 0.2469 0.1475 0.6409 0.9084 0.5793 0.9643 0.2258 0.2258 0.2258
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromh Deep venous th Atrial fibrillati Pulmonary eml Peripheral arter Inchemic stroka Intracerebral hu Subarachnoid I Cerebral infare	rrosclerosis hy hy hy hy hy hy hy hy hy hy	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinnGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et al) Neale lab Consortium (Malik et al) The FinnGen consortium The FinnGen consortium	42,096/89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/356,574 9,241/453,692 60,620,970,216 60,620,970,216 1,456/461,554 1,456/461,554 1,456/461,554 1,687/201,146 1,961/281,638	European European	Exposure O CD 0 CD 0 UC 1 CD 0 UC 0 CD 0 UC 0 UC 0 UC 0 UC 0 CD 0 UC 1 CD 0 UC 1 UC 1 UC 1 UC 1 CD 0 UC 1	R 9:9 R 9:9 0.000 0. 9:9091 0.0009 0. 0. 9:9092 0.0009 0. 0. 9:9093 0. 0. 9. 9:9093 0. 0. 9. 9:9094 0. 0. 9. 9:9095 0. 0. 0. 9:9095 0. 0. 0. 9:9096 0. 0. 0. 9:9095 0. 0. 0. 9:9096 0. 0. 0. 9:9097 0. 0. 0. 9:9098 0. 0. 0. 9:9098 0. 0. 0. 9:90990 0. 0. 0. 9:9098 0. 0. 0. 0:00058 0. 0. 0. 0:00058 0. 0. 0. 0:00058 0. 0. 0.	5%C1 9875-1077 99764-1.0260 9995-1.0008 9995-1.0008 9995-1.0002 9995-1.0002 9972-1.0116 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0003 9995-1.0003 9997-1.0002 9996-1.0001 9997-1.0002 9328-1.0173 9344-1.0278					1	P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9187 0.9187 0.9187 0.8258 0.5384 0.8258 0.3841 0.8258 0.8258 0.8113 0.2669 0.1475 0.6409 0.9084 0.5703 0.9013 0.9086 0.2258 0.2258
Coronary heart Coronary ather Heart failure Cardiomyopath Venous thromh Deep venous th Atrial fibrillatis Pulmonary em Peripheral artee Ischemic stroko Intracerebral h Subarachnoid I	rrosclerosis hy hy hy hy hy hy hy hy hy hy	CARDIOGRAMplusC4D Neale lab Consortium (Shah S et al.) The FianGen consortium Neale lab NRC-IEU Consortium (Jonas B. Nielsen et.al) Neale lab Consortium (Malik et.al) The FianGen consortium	42,096/ 89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/ 356,574 9,241/453,692 60,620,970,216 60,620,970,216 1,456/461,554 34,217/406,111 1,687/201,146 1,961/281,638	European European	Exposure G CD 0 CD 1 CD 1 CD 1 CD 0 UC 1 CD 0 UC 1 CD 0 UC 1 CD 1 CD 1 CD 1 (CD)	R 9:9 R 9:9991 0. 0.0009 0. 0. 0.0001 0. 0. 0.0001 0. 0. 9.9975 0. 0. 9.9975 0. 0. 9.9976 0. 0. 9.9995 0. 0. 9.9995 0. 0. 0.0003 0. 0. 0.0003 0. 0. 0.0003 0. 0. 9.9998 0. 0. 9.9998 0. 0. 9.9998 0. 0. 9.9998 0. 0. 9.9998 0. 0. 9.9998 0. 0. 9.9916 0. 0. 9.9958 0. 0. 9.9581 0. 0. 9.9581 0. 0. 9.9581 0. 0. 9.9581 0. 0.	5%C1 9814-10171 9764-10260 9995-1.0008 9995-1.0008 9983-1.0002 99824-10129 9772-1.0116 91924-0128 9324-1021 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0004 9997-1.0002 9997-1.0002 9997-1.0002 9997-1.0002 9997-1.0002 9984-1.002 9984-1.002 9984-1.0028 9984-1.0028 9984-1.0028 99828-1.1173						P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658 0.5134 0.8258 0.1973 0.9695 0.8113 0.2469 0.1475 0.6409 0.9084 0.5793 0.9613 0.8088 0.2258 0.2254 0.2846
Coronary heart Coronary ather Heart failure Cardiomyopath Venous throml Deep venous th Atrial fibrillati Pulmonary eml Peripheral arter Ischemic stroka Intracerebral hu Subarachnoid I Cerebral infare	rrosclerosis hy hy hy hy hy hy hy hy hy hy	CARDIoGRAMplusC4D Neale lab Consortium (Shah S et al.) The FinnGen consortium Neale lab MRC-IEU Consortium (Jonas B. Nielsen et al) Neale lab Consortium (Malik et al) The FinnGen consortium The FinnGen consortium	42,096/89,818 14,334/346,860 47,309/930,014 4,606/218,984 4,620/356,574 9,241/453,692 60,620,970,216 60,620,970,216 1,456/461,554 1,456/461,554 1,456/461,554 1,687/201,146 1,961/281,638	European European	Exposure G CD 0 CD 1 CD 1 CD 1 CD 0 UC 1 CD 0 UC 1 CD 0 UC 1 CD 1 CD 1 CD 1 (CD)	R 9:9 R 9:9991 0. 0.0009 0. 0. 0.0001 0. 0. 0.0001 0. 0. 9.9975 0. 0. 9.9975 0. 0. 9.9976 0. 0. 9.9995 0. 0. 9.9995 0. 0. 0.0003 0. 0. 0.0003 0. 0. 0.0003 0. 0. 9.9998 0. 0. 9.9998 0. 0. 9.9998 0. 0. 9.9998 0. 0. 9.9998 0. 0. 9.9998 0. 0. 9.9916 0. 0. 9.9958 0. 0. 9.9581 0. 0. 9.9581 0. 0. 9.9581 0. 0. 9.9581 0. 0.	5%C1 9875-1077 99764-1.0260 9995-1.0008 9995-1.0008 9995-1.0002 9995-1.0002 9972-1.0116 9995-1.0004 9995-1.0004 9995-1.0004 9995-1.0003 9995-1.0003 9997-1.0002 9996-1.0001 9997-1.0002 9328-1.0173 9344-1.0278						P Value 0.9242 0.9457 0.8701 0.1356 0.7502 0.5131 0.1487 0.9186 0.8030 0.0658 0.8258 0.8258 0.8258 0.8258 0.8258 0.8113 0.2649 0.1475 0.6409 0.9084 0.5733 0.9613 0.8083 0.8258 0.2258

FIGURE 1

Associations of genetically predicted IBD with risk of 14 CVD outcomes. (A) Random-effect. (B) Fix-effect. UC, ulcerative colitis; CD, Crohn's disease; MRC-IEU: MRC Integrative Epidemiology Unit.


website. The data are free to download and can be used without restrictions.

We selected SNPs that were strongly associated with IBD of genome-wide significance ($P < 5 \times 10^{-8}$) and pruned SNPs in linkage disequilibrium ($R^2 > 0.001$ within a 10,000 kb window) with the clump data function in the TwoSampleMR² software package in R (25)

(Supplementary material 1). In addition, we used the PhenoScanner³ tool to exclude any of the selected SNPs associated with other phenotypes at risk of affecting CVD outcomes. These rigorously selected SNPs were used as the final SNPs for subsequent MR analysis (Figure 2) (26–28). The strength of the genetic instruments was indicated by the *F*-statistic.

² https://mrcieu.github.io/TwoSampleMR/reference/clump_data.html

³ http://www.phenoscanner.medschl.cam.ac.uk/



Mendelian randomization

We used two-sample MR, a powerful statistical method, to infer the causality between the two phenotypes. To obtain MR estimate, an inverse-variance weighted (IVW) meta-analysis of each Wald ratio was performed, which is considered the most reliable when there is no evidence of directional pleiotropy (29). The MR-PRESSO method was used to detect outlier variables in IVW analysis by comparing the actual distance of the genetic variants to the expected distance from the regression, assuming the absence of horizontal pleiotropy, and evaluating the causal estimates after removing outliers (30). We also used alternative analyses, including IVW (fixed effects), MR Egger, maximum likelihood, weighted median, penalized weighted media, simple mode, and weighted mode method. Associations were considered statistically significant at a Bonferroni corrected P-value below 0.0018 (correcting for 2 exposures and 14 outcomes).

Pleiotropy and sensitivity analysis

Inverse-variance weighted and MR-Egger regression were used to detect heterogeneity. Cochran's Q test was used to quantify heterogeneities, and P < 0.05 was considered statistically significant. Horizontal pleiotropy tests were

performed by judging the intercept term in MR-Egger regression. If the intercept term was close to 0 (<0.1) and P > 0.05, it indicated that there was no evidence of horizontal pleiotropy in the analysis, showing that the results of MR analyses were reliable. Asymmetry in a funnel plot is also useful for gauging the reliability of a particular MR analyses. Furthermore, sensitivity analysis was performed for qualified CVDs using the leave-one-out method, where the MR was performed again but leaving out each SNP in turn, to determine whether a single SNP was driving the association.

Mendelian randomization analysis were performed using the "TwoSampleMR" and "MR-PRESSO" R package version 0.4.13.⁴ The power of MR was calculated by mRnD.⁵

Results

Single nucleotide polymorphisms selected in Mendelian randomization

We obtained 88 SNPs in ulcerative colitis and 122 SNPs in Crohn's disease, which met the generally accepted genomewide significance threshold ($P < 5 \times 10^{-8}$, $r^2 < 0.001$,

⁴ http://github.com/MRCIEU/TwoSampleMR

⁵ https://shiny.cnsgenomics.com/mRnd/

kb = 10,000) for exposure (Supplementary material 1). To remove confounding factors, 7 SNPs (rs11229555, rs13430791, rs1801274, rs2516440, rs3024493, rs6062496, and rs9271255) in ulcerative colitis and 11 SNPs (rs17622378, rs2641348, rs3024505, rs3129871, rs3184504, rs516246, rs6062496, rs61839660, rs6679677, rs77981966, and rs780094) in Crohn's disease were eliminated, which were strongly associated with diabetes, total cholesterol, and smoking. Moreover, estimates of the *F*-statistic indicated no weak instrument bias (all *F*-statistic > 10).

Association between inflammatory bowel disease and cardiovascular disease risks

Mendelian randomization analysis showed that there was no significant association of IBD with CVD outcomes (all P > 0.05) (Figure 1). The result was consistent with IVW (fixed effects), maximum likelihood, weighted medium, penalized weighted media, and MR-PRESSO (Supplementary material 2). The effect size of each SNP on CVDs is shown in Supplementary materials 3, 4.

Sensitivity analyses

For sensitivity analyses, Cochran's *Q* test indicated no evidence of heterogeneity (**Supplementary material 5**). The horizontal pleiotropy between SNPs and outcome was assessed by MR-Egger regression, and the results showed that there was no evidence of horizontal pleiotropy (**Supplementary material 5**). The funnel plot displayed symmetric pattern of effect size variation around the point estimate, again indicating no apparent horizontal pleiotropy (**Supplementary materials 3, 4**). The results of leave-one-out sensitivity analyses demonstrated that there was no potentially influential SNP driving the causal link and the stability of our conclusion (**Supplementary materials 3, 4**).

Discussion

In this study, a two-sample MR analysis was performed to evaluate the causal effect of IBD on CVD outcomes for the first time. MR analysis did not indicate detrimental effects of genetic increase in IBD on the risk of CVDs. These results were stable in sensitivity analysis by using different Mendelian tools and statistical models, indicating that our analysis is reliable.

Over the past several years, a growing number of observational studies have indicated that IBD is related to an increased risk of CVD outcomes, especially in the active period of IBD, which has been described in studies on large populations (31–33). Meta-analysis showed that there was a positive correlation between IBD and higher incidence of ischemic heart disease and cerebrovascular accidents (11, 34). However, the mechanism of this increased risk remains unclear. Recent fundamental research has suggested that changes in the innate and adaptive immune systems induce an increase in proinflammatory factors and promote the formation of thrombosis and atherosclerosis (35). In addition, changes in gut microbiota composition in patients with IBD may contribute to intestinal epithelial cell apoptosis and barrier dysfunction (36). Both lipopolysaccharide translocation and initiation of an inflammatory cascade result in dysfunction of microvascular and macrovascular endothelial function (37).

Inflammatory bowel disease is less likely to increase the risk of CVD (38). A study that included 31,175 IBD patients (16,779 ulcerative colitis, 10,721 Crohn's disease, and 3,675 unclassifiable cases) and 154,412 matched controls showed no significant excess of vascular events for IBD patients overall. After adjusting for confounders such as smoking, the risk of stroke, and coronary heart disease was reduced in patients with IBD (39). A meta-analysis also showed that no increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease (39, 40). These results are somewhat inconsistent with previously published observational studies, with a number of possible explanations for this inconsistency. Firstly, the discrepancy between findings from different study designs may be explained by the susceptibility to confound such as socioeconomic, dietary, and lifestyle behavioral factors in traditional observational studies. Hartwig et al. (41) indicated that the risk of coronary artery disease in IBD patients was not increased compared with normal people after excluding traditional risk factors. Thus, we speculated that IBD patients have increased levels of traditional cardiovascular risk factors, resulting in an increased incidence of CVD in observational studies. Recent MR studies showed a lack of genetic causality between IBD and atrial fibrillation (42), which was consistent with our results. Although pleiotropy may cause the bias of the results in MR analysis, there is little possibility in our study (43). Because our MR analysis had more than 80% power to detect the effect of CVDs development (Supplementary material 5). Nonetheless, a very small effect of IBD on CVD outcomes could not be excluded because of tight confidence intervals.

Strengths and limitations

The main strength of this study is that we used a twosample MR analysis to assess independent effects of the IBD on multiple CVD outcomes, offering the possibility to overcome several limitations in conventional epidemiological studies. As alleles are randomly assorted and fixed at conception, bias caused by reverse causation can be largely avoided (44). An additional strong point is the large scale of the samples size that enabled us to conduct well-powered MR analyses. Finally, our results were unlikely to be impacted by population stratification bias for the sake of GWAS, which comprised individuals who were primarily of European ancestry (45). In addition, we used the STROBE-MR checklist of recommended items to address in reports of MR studies to check our study (Supplementary material 6).

Inevitably, this study had certain limitations. Although we used the GWAS dataset, due to the lack of original data, we could not fully analyze the staging of IBD (such as IBD with periods of disease activation and remission). Therefore, additional MR analysis are still required to estimate the causal relationship between different stages of IBD and CVD outcomes. Though our results suggested that IBD does not increase the risk of CVD outcomes, we could not completely rule out the possibility. A definitive causal relationship requires more in-depth mechanism studies and RCTs in the future.

Conclusion

In this study, we assessed the causal effect of IBD (ulcerative colitis and Crohn's disease) on the increased risk of CVD outcomes by using a two-sample MR analysis. Our results suggested that genetically predicted IBD has no clear causal effect on CVD outcomes. Therefore, further updated MR analysis should be conducted to confirm our results when more advanced methods and more IBD patients are available to obtain less bias estimation and more accurate accuracy.

Data availability statement

Publicly available datasets were analyzed in this study. The data of ulcerative colitis (ID: ieu-a-970), Crohn's disease (ID: ieu-a-12), coronary artery disease (ID: ieu-a-7), coronary atherosclerosis (ID: ukb-d-I9_CORATHER), heart failure (ID: ebi-a-GCST009541), venous thromboembolism (ID: ukb-d-I9_VTE), deep venous thrombosis (ID: ukb-b-12040), atrial fibrillation (ID: ebi-a-GCST006414), pulmonary embolism (ID: ukb-d-I26), peripheral arterial disease (ID: ukb-b-4929), ischemic stroke (ID: ebi-a-GCST006908), intracerebral hemorrhage (ID: finn-b-I9_ICH), and cerebral infarction (ID: ukb-b-19350) can be obtained from https://gwas.mrcieu.ac.uk/. The data of cardiomyopathy (ID: Finngen-R7-I9-CARDMYO), subarachnoid hemorrhage (ID: Finngen-R7-I9- SAH), and atherosclerosis (ID: Finngen-R7-I9-ATHSCLE) can be obtained from https://www.finngen.fi/en. The R code to perform the MR analysis is detailed in Supplementary material 7.

Ethics statement

Ethical review and approval was not required for this study in accordance with the local legislation and institutional requirements.

Author contributions

XS designed the study. DX and KW wrote the manuscript. KW and AL contributed to the data analysis and data interpretation. LL and TS contributed to the revision of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the Foundation of Science and Technology, Department of Sichuan Province (2020YJ0485).

Acknowledgments

We thank all of the investigators for sharing summary-level data on GWAS for IBD and CVDs.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fcvm.2022.927120/full#supplementary-material

SUPPLEMENTARY MATERIAL 1

Instrumental SNPs from ulcerative colitis and Crohn's disease GWASs.

SUPPLEMENTARY MATERIAL 2

Mendelian randomization estimates from each method of the causal effect of inflammatory bowel disease on CVDs.

SUPPLEMENTARY MATERIAL 3

Mendelian randomization effect size, leave-one-out analyses, and funnel plot for ulcerative colitis on CVDs.

SUPPLEMENTARY MATERIAL 4

Mendelian randomization effect size, leave-one-out analyses, and funnel plot for Crohn's disease on CVDs.

References

1. Roth GA, Mensah GA, Fuster V. The global burden of cardiovascular diseases and risks: A compass for global action. *J Am Coll Cardiol.* (2020) 76:2980–1. doi: 10.1016/j.jacc.2020.11.021

2. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. *Circulation.* (2019) 140:e596–646. doi: 10.1161/cir.00000000000678

3. Roger VL, Sidney S, Fairchild AL, Howard VJ, Labarthe DR, Shay CM, et al. Recommendations for cardiovascular health and disease surveillance for 2030 and beyond: A policy statement from the American heart association. *Circulation.* (2020) 141:e104–19. doi: 10.1161/cir.000000000000756

4. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study. *Lancet.* (2020) 395:795–808. doi: 10.1016/s0140-6736(19)32008-2

5. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol.* (2021) 18:56–66. doi: 10.1038/s41575-020-00360-x

6. Gbd 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. *Lancet Gastroenterol Hepatol.* (2020) 5:17–30. doi: 10.1016/s2468-1253(19)30333-4

7. Chen L, Sun X, Wang Z, Lu Y, Chen M, He Y, et al. The impact of plasma vitamin C levels on the risk of cardiovascular diseases and Alzheimer's disease: A Mendelian randomization study. *Clin Nutr.* (2021) 40:5327–34. doi: 10.1016/j.clnu. 2021.08.020

8. Bigeh A, Sanchez A, Maestas C, Gulati M. Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease? *Trends Cardiovasc Med.* (2020) 30:463–9. doi: 10.1016/j.tcm.2019.10.001

9. Lykowska-Szuber L, Rychter AM, Dudek M, Ratajczak AE, Szymczak-Tomczak A, Zawada A, et al. What links an increased cardiovascular risk and inflammatory bowel disease? A narrative review. *Nutrients* (2021) 13:2661. doi: 10.3390/nu13082661

10. Rungoe C, Basit S, Ranthe MF, Wohlfahrt J, Langholz E, Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: A nationwide Danish cohort study. *Gut.* (2013) 62:689–94. doi: 10.1136/gutjnl-2012-303285

11. Sun HH, Tian F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: A meta-analysis. *European J Prev Cardiol.* (2018) 25:1623–31. doi: 10.1177/2047487318792952

12. Filimon AM, Negreanu L, Doca M, Ciobanu A, Preda CM, Vinereanu D. Cardiovascular involvement in inflammatory bowel disease: Dangerous liaisons. *World J Gastroenterol.* (2015) 21:9688–92. doi: 10.3748/wjg.v21.i33.9688

13. Sridhar AR, Parasa S, Navaneethan U, Crowell MD, Olden K. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. *J Crohns Colitis.* (2011) 5:287–94. doi: 10.1016/j.crohns.2011.01. 011

14. Venkatesh SS, Ferreira T, Benonisdottir S, Rahmioglu N, Becker CM, Granne I, et al. Obesity and risk of female reproductive conditions: A Mendelian randomisation study. *PLoS Med.* (2022) 19:e1003679. doi: 10.1371/journal.pmed. 1003679

15. Wu F, Huang Y, Hu J, Shao Z. Mendelian randomization study of inflammatory bowel disease and bone mineral density. *BMC Med.* (2020) 18:312. doi: 10.1186/s12916-020-01778-5

SUPPLEMENTARY MATERIAL 5

Heterogeneity, level pleiotropy test, and the power of Mendelian randomization analyses.

SUPPLEMENTARY MATERIAL 6

STROBE-MR checklist of recommended items to address in reports of MR studies.

SUPPLEMENTARY MATERIAL 7

The R code was used to perform Mendelian randomization.

16. Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. *JAMA*. (2017) 318:1925–6. doi: 10.1001/jama.2017.17219

17. Zong Y, Li X. Identification of causal genes of COVID-19 using the SMR method. Front Genet. (2021) 12:690349. doi: 10.3389/fgene.2021.690349

18. Yarmolinsky J, Relton CL, Lophatananon A, Muir K, Menon U, Gentry-Maharaj A, et al. Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. *PLoS Med.* (2019) 16:e1002893. doi: 10.1371/journal.pmed.1002893

19. Larsson SC, Michaëlsson K, Burgess S. Mendelian randomization in the bone field. *Bone*. (2019) 126:51–8. doi: 10.1016/j.bone.2018.10.011

20. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet.* (2015) 47:979–86. doi: 10.1038/ng.3359

21. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nat Commun.* (2020) 11:163. doi: 10.1038/s41467-019-13690-5

22. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet.* (2011) 43:333–8. doi: 10.1038/ng.784

23. Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. *Nat Genet.* (2018) 50:1234–9. doi: 10.1038/s41588-018-0 171-3

24. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet.* (2018) 50:524–37. doi: 10.1038/s41588-018-0058-3

25. Howe LJ, Battram T, Morris TT, Hartwig FP, Hemani G, Davies NM, et al. Assortative mating and within-spouse pair comparisons. *PLoS Genet.* (2021) 17:e1009883. doi: 10.1371/journal.pgen.1009883

26. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: A report from the American heart association. *Circulation*. (2022) 145:e153–639. doi: 10.1161/cir. 000000000001052

27. Cui Z, Tian Y. Using genetic variants to evaluate the causal effect of serum vitamin D concentration on COVID-19 susceptibility, severity and hospitalization traits: A Mendelian randomization study. *J Transl Med.* (2021) 19:300. doi: 10.1186/s12967-021-02973-5

28. He Q, Yang Z, Sun Y, Qu Z, Jia X, Li J, et al. The impact of homocysteine on the risk of hormone-related cancers: A Mendelian randomization study. *Front Nutr.* (2021) 8:645371. doi: 10.3389/fnut.2021.645371

29. Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: Challenges in evaluating causality. *Nat Rev Cardiol.* (2017) 14:577–90. doi: 10.1038/nrcardio.2017.78

30. Choi KW, Chen CY, Stein MB, Klimentidis YC, Wang MJ, Koenen KC, et al. Assessment of bidirectional relationships between physical activity and depression among adults: A 2-sample Mendelian randomization study. *JAMA Psychiatry.* (2019) 76:399–408. doi: 10.1001/jamapsychiatry.2018.4175

31. Shen X, Wan Q, Zhao R, Wu Y, Wang Y, Cui Y, et al. Inflammatory bowel diseases and the risk of adverse health outcomes: Umbrella review of meta-analyses of observational studies. *Dig Liver Dis.* (2021) 53:809–16. doi: 10.1016/j.dld.2021. 01.018

32. Nevulis MG, Baker C, Lebovics E, Frishman WH. Overview of link between inflammatory bowel disease and cardiovascular disease. *Cardiol Rev.* (2018) 26:287–93. doi: 10.1097/crd.0000000000214

33. Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. *J Crohns Colitis.* (2016) 10:239–54. doi: 10.1093/ecco-jcc/jjv213

34. Feng W, Chen G, Cai D, Zhao S, Cheng J, Shen H. Inflammatory bowel disease and risk of ischemic heart disease: An updated meta-analysis of cohort studies. *J Am Heart Assoc.* (2017) 6:e005892. doi: 10.1161/jaha.117.00 5892

35. Kamperidis N, Kamperidis V, Zegkos T, Kostourou I, Nikolaidou O, Arebi N, et al. Atherosclerosis and inflammatory bowel disease-shared pathogenesis and implications for treatment. *Angiology.* (2021) 72:303–14. doi: 10.1177/0003319720974552

36. Tang WH, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. *Circ Res.* (2017) 120:1183–96. doi: 10.1161/circresaha.117.309715

37. McDonnell M, Liang Y, Noronha A, Coukos J, Kasper DL, Farraye FA, et al. Systemic toll-like receptor ligands modify B-cell responses in human inflammatory bowel disease. *Inflamm Bowel Dis.* (2011) 17:298–307. doi: 10.1002/ibd.21424

38. Gill GS, Fernandez SJ, Malhotra N, Mete M, Garcia-Garcia HM. Major acute cardiovascular events in patients with inflammatory bowel disease. *Coron Artery Dis.* (2021) 32:73–7. doi: 10.1097/mca.00000000000899

39. Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: A population-based cohort study. *Circulation.* (2014) 130:837–44. doi: 10.1161/circulationaha.114.009990

40. Rungoe C, Nyboe Andersen N, Jess T. Inflammatory bowel disease and risk of coronary heart disease. *Trends Cardiovasc Med.* (2015) 25:699–704. doi: 10.1016/j.tcm.2015.03.010

41. Hartwig FP, Borges MC, Horta BL, Bowden J, Davey Smith G. Inflammatory biomarkers and risk of schizophrenia: A 2-sample Mendelian randomization study. *JAMA Psychiatry*. (2017) 74:1226–33. doi: 10.1001/jamapsychiatry.2017. 3191

42. Chen L, Fu G, Jiang C. Mendelian randomization as an approach to assess causal effects of inflammatory bowel disease on atrial fibrillation. *Aging.* (2021) 13:12016–30. doi: 10.18632/aging.202906

43. Huang G, Cai J, Li W, Zhong Y, Liao W, Wu P. Causal relationship between educational attainment and the risk of rheumatoid arthritis: A Mendelian randomization study. *BMC Rheumatol.* (2021) 5:47. doi: 10.1186/s41927-021-00216-0

44. Fu Y, Xu F, Jiang L, Miao Z, Liang X, Yang J, et al. Circulating vitamin C concentration and risk of cancers: A Mendelian randomization study. *BMC Med.* (2021) 19:171. doi: 10.1186/s12916-021-02041-1

45. Larsson SC, Mason AM, Bäck M, Klarin D, Damrauer SM, Michaëlsson K, et al. Genetic predisposition to smoking in relation to 14 cardiovascular diseases. *Eur Heart J.* (2020) 41:3304–10. doi: 10.1093/eurheartj/ehaa193